ArticleCancer management and research2020
Circ_0062020 Knockdown Strengthens the Radiosensitivity of Prostate Cancer Cells.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Prognostic and diagnostic value of circRNA expression in prostate cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- The Emerging Role of Circular RNAs in Prostate Cancer: A Systematic Review.Frontiers in cell and developmental biology · 2021Pooled it
- Multiple roles of circular RNAs in prostate cancer: from the biological basis to potential clinical applications.European journal of medical research · 2025Review
- Role of circular RNAs in cancer therapy resistance.Molecular cancer · 2025Review
- Role of Circular RNAs in Prostate Cancer.Current medicinal chemistry · 2024Review
- The function and mechanisms of action of circular RNAs in Urologic Cancer.Molecular cancer · 2023Review
- CircRNAs in Tumor Radioresistance.Biomolecules · 2022Review
- Mechanism and Function of Circular RNA in Regulating Solid Tumor Radiosensitivity.International journal of molecular sciences · 2022Review
- Circular RNA hsa_circ_0004396 acts as a sponge of miR-615-5p to promote non-small cell lung cancer progression and radioresistance through the upregulation of P21-Activated Kinase 1.Journal of clinical laboratory analysis · 2022Article
- Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.Journal of experimental & clinical cancer research : CR · 2022Review
- Circ_0007580 knockdown strengthens the radiosensitivity of non-small cell lung cancer via the miR-598-dependent regulation of THBS2.Thoracic cancer · 2022Article
- A Circ-0007022/miR-338-3p/Neuropilin-1 Axis Reduces the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Activating Epithelial-To-Mesenchymal Transition and PI3K/AKT Pathway.Frontiers in genetics · 2022Article
- CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers.Frontiers in oncology · 2022Review
- Circular RNAs in prostate cancer: Biogenesis,biological functions, and clinical significance.Molecular therapy. Nucleic acids · 2021Review
- The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential.Cancer communications (London, England) · 2021Review
- Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer.Cell death & disease · 2021Article
- Hsa_circRNA_100146 Promotes Prostate Cancer Progression by Upregulating TRIP13Frontiers in molecular biosciences · 2021Article
- The Role and Clinical Potentials of Circular RNAs in Prostate Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is a major contributor to reduce the life quality of males. Circular RNAs were frequently reported to be associated with cancers. In the case of radiotherapy to PCa, the role of circ_0062020 was still inconclusive, which was further explored in this study.
methodsQuantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the expression of circ_0062020, miR-615-5p and thyroid hormone receptor interactor 13 (TRIP13) in PCa tissues and cells, as well as in normal tissues and cell. Meanwhile, the proliferation of PCa cells was evaluated by clone formation assay and cell counting kit 8 (CCK8) assay. Moreover, the metastasis of PCa cells was assessed by transwell and wound healing assays. Furthermore, the apoptosis of PCa cells was determined by flow cytometry assay. Besides, dual-luciferase reporter system was applied to verify the correlation between miR-615-5p and circ_0062020 or TRIP13, which was predicted by online tool CircRNA interactome or TargetScan. In addition, the protein expression of TRIP13 was measured by Western blot in PCa tissues and cells and normal tissues and cells. Finally, xenograft tumor assay was performed to further confirming the function of circ_0062020 in PCa in vivo.
resultsCirc_0062020 and TRIP13 were upregulated, while miR-615-5p was downregulated in PCa tissues and cells. Circ_0062020 knockdown or miR-615-5p overexpression inhibited the proliferation and metastasis, and promoted apoptosis, which could be reversed by miR-615-5p inhibitor or pc-TRIP13 in ionizing radiation (IR)-treated PCa cells. As expected, circ_0062020 sponged miR-615-5p to regulate TRIP13 expression in PCa cells. Circ_0062020 knockdown also suppressed PCa tumor growth in vivo.
conclusionCirc_0062020 suppressed the radiosensitivity by miR-615-5p/TRIP13 axis in PCa cells, which might provide insights into the radiotherapy for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.